Rosetta Genomics is a leading molecular diagnostics company advancing minimally-invasive molecular tests based on its proprietary microRNAs, and platform technologies. Following the launch of three cancer tests in the beginning of 2009, the Company is now working to develop cancer screening products, including a colon cancer screening test.
June 17, 2009
Rosetta Genomics passes California, Maryland, and Rhode Island CLIA insepctions; Files 2008 audited financial statement on form 6-k....More
June 8, 2009
Rosetta Genomics to present at the Eighth Annual Needham and Company Biotechnology and Medical Technology Conference....More
